0001062993-23-013930.txt : 20230621 0001062993-23-013930.hdr.sgml : 20230621 20230621173256 ACCESSION NUMBER: 0001062993-23-013930 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230620 FILED AS OF DATE: 20230621 DATE AS OF CHANGE: 20230621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PETERSON TYCHO CENTRAL INDEX KEY: 0001927856 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 231030956 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0407 4 2023-06-20 0001478320 Adaptive Biotechnologies Corp ADPT 0001927856 PETERSON TYCHO C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1165 EASTLAKE AVENUE EAST SEATTLE WA 98109 0 1 0 0 Chief Financial Officer 1 Common Stock 2023-06-20 4 M 0 134961 7.30 A 534180 D Common Stock 2023-06-20 4 S 0 70000 8.14 D 464180 D Common Stock 2023-06-20 4 S 0 64961 8.14 D 399219 D Stock Option (right to buy) 7.30 2023-06-20 4 M 0 134961 0 D 2032-06-01 Common Stock 134961 447868 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.00 to $8.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The options vested with respect to 1/4 of such shares on June 1, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Tycho Peterson by Stacy L Taylor, Attorney-in-Fact 2023-06-21